FR940816-2-00073 FR940816-2-00056 5. Support the execution of clinical trials designed to evaluate efficacy and toxicity. This may include providing pharmaceutical grade compound, equipment and supplies, and support personnel. 6. Provide new and improved formulations in appropriate vehicles. Selection criteria for choosing the CRADA partner(s) will include but not be limited to: 1. Ability to complete the quality pharmacological evaluations required according to an appropriate timetable to be outlined in the Collaborator's proposal. The target commercial application as well as the strategy for evaluating the test agents' potential in that capacity must be clearly delineated therein. 2. The level of financial support the Collaborator will supply for CRADA-related Government activities. 3. A willingness to cooperate with the NEI, NIAMS, and NICHD in publication of research results. 4. An agreement to be bound by the DHHS rules involving human subjects, patent rights, ethical treatment of animals, and randomized clinical trials. 5. Agreement with provisions for equitable distribution of patent rights to any inventions developed under the CRADA(s). Generally, the rights of ownership are retained by the organization which is the employer of the inventor, with (1) an irrevocable, non-exclusive, royalty-free license to the Government (when a company employee is the sole inventor) or (2) an option to negotiate an exclusive or non-exclusive license to the company on terms that are appropriate (when the Government employee is the sole inventor). Dated: August 8, 1994. Barbara M. McGarey, Deputy Director, Office of Technology Transfer. [FR Doc. 94&hyph;19942 Filed 8&hyph;15&hyph;94; 8:45 am] BILLING CODE 4140&hyph;01&hyph;P
